Cambridge Investment Research Advisors, Inc. Silence Therapeutics PLC Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,194 shares of SLN stock, worth $73,090. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,194Holding current value
$73,090% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SLN
# of Institutions
57Shares Held
20.6MCall Options Held
22.8KPut Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$21.8 Million3.59% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$20.9 Million0.87% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$15.5 Million1.53% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.85MShares$13.3 Million0.9% of portfolio
-
Morgan Stanley New York, NY1.21MShares$8.69 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $257M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...